An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

• Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.

Exclusion Criteria:

• Known or documented brain metastases prior to Cetuximab therapy.